Imaging software developer Median Technologies has signed a three-year collaborative agreement with South Texas Accelerated Research Therapeutics (START).
With centers located in San Antonio and Madrid, START conducts the world's largest phase I medical oncology program, putting more than 400 patients per year in phase I trials, according to Median. START's mission is to accelerate the development of new anticancer drugs that will improve the quality of life and survival for patients.
According to the terms of the agreement, Median's Lesion Management Solutions (LMS) software application will be used for image interpretation and management during phase I oncology trials conducted by START. The objective is to provide START with imaging tools to assess patient response to therapy based on the implementation of standard imaging criteria, such as RECIST1, and advanced imaging biomarkers, such as tumor volume.
